cd19-ucart

CLL

University Hospital TuebingenCell therapyPhase 1/2Active

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the CLL cohort.

Asset / Sponsor	Phase	Rating
Ppsv23 Region Örebro County	Phase 4	BB
Conjugated Pneumococcal Vaccine Region Örebro County	Phase 4	BB
Benadryl National Cancer Institute (NCI)	Phase 2	B
sb-497115-gr University of Ulm	Phase 2	B
Gm-Csf Beth Israel Deaconess Medical Center	Phase 2	B

View all 22 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant

BBB

Indicative ·

72 / 100

B-cell non-Hodgkin lymphomaDormant

BB

Indicative ·

71 / 100

B-cell acute lymphoblastic leukemiaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.